Phocas Financial Corp. Reduces Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Phocas Financial Corp. lessened its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 5.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,015,190 shares of the company's stock after selling 63,485 shares during the quarter. Phocas Financial Corp. owned approximately 0.33% of Amneal Pharmaceuticals worth $8,446,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in shares of Amneal Pharmaceuticals during the third quarter valued at approximately $84,000. Gladius Capital Management LP acquired a new stake in shares of Amneal Pharmaceuticals in the third quarter valued at about $37,000. Victory Capital Management Inc. boosted its position in Amneal Pharmaceuticals by 58.7% during the third quarter. Victory Capital Management Inc. now owns 99,215 shares of the company's stock worth $825,000 after acquiring an additional 36,700 shares during the last quarter. Aigen Investment Management LP acquired a new position in Amneal Pharmaceuticals during the third quarter worth $213,000. Finally, Versor Investments LP grew its holdings in shares of Amneal Pharmaceuticals by 191.3% in the third quarter. Versor Investments LP now owns 40,200 shares of the company's stock valued at $334,000 after purchasing an additional 26,400 shares during the period. 31.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on AMRX shares. Barclays increased their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 13th. Piper Sandler boosted their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, November 11th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 target price for the company in a research note on Friday, September 6th. StockNews.com raised shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Monday, November 11th. Finally, Truist Financial raised their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Wednesday, October 2nd. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Amneal Pharmaceuticals has an average rating of "Buy" and an average target price of $10.00.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock traded up $0.05 during mid-day trading on Tuesday, reaching $8.38. The company had a trading volume of 424,209 shares, compared to its average volume of 1,403,994. The stock's 50-day simple moving average is $8.57 and its 200-day simple moving average is $7.68. Amneal Pharmaceuticals, Inc. has a 1 year low of $4.16 and a 1 year high of $9.48. The company has a market capitalization of $2.59 billion, a P/E ratio of -12.25 and a beta of 1.17.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.